223 related articles for article (PubMed ID: 23578674)
1. MR imaging features of amyloid-related imaging abnormalities.
Barakos J; Sperling R; Salloway S; Jack C; Gass A; Fiebach JB; Tampieri D; Melançon D; Miaux Y; Rippon G; Black R; Lu Y; Brashear HR; Arrighi HM; Morris KA; Grundman M
AJNR Am J Neuroradiol; 2013 Oct; 34(10):1958-65. PubMed ID: 23578674
[TBL] [Abstract][Full Text] [Related]
2. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.
Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM
J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765
[TBL] [Abstract][Full Text] [Related]
3. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.
Sperling R; Salloway S; Brooks DJ; Tampieri D; Barakos J; Fox NC; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Lieberburg I; Arrighi HM; Morris KA; Lu Y; Liu E; Gregg KM; Brashear HR; Kinney GG; Black R; Grundman M
Lancet Neurol; 2012 Mar; 11(3):241-9. PubMed ID: 22305802
[TBL] [Abstract][Full Text] [Related]
5. Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies.
Brashear HR; Ketter N; Bogert J; Di J; Salloway SP; Sperling R
J Alzheimers Dis; 2018; 66(4):1409-1424. PubMed ID: 30412493
[TBL] [Abstract][Full Text] [Related]
6. The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study.
Martens RM; Bechten A; Ingala S; van Schijndel RA; Machado VB; de Jong MC; Sanchez E; Purcell D; Arrighi MH; Brashear RH; Wattjes MP; Barkhof F
Eur Radiol; 2018 Mar; 28(3):1215-1226. PubMed ID: 28956123
[TBL] [Abstract][Full Text] [Related]
7. An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion.
Barkhof F; Daams M; Scheltens P; Brashear HR; Arrighi HM; Bechten A; Morris K; McGovern M; Wattjes MP
AJNR Am J Neuroradiol; 2013 Aug; 34(8):1550-5. PubMed ID: 23436056
[TBL] [Abstract][Full Text] [Related]
8. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.
Barakos J; Purcell D; Suhy J; Chalkias S; Burkett P; Marsica Grassi C; Castrillo-Viguera C; Rubino I; Vijverberg E
J Prev Alzheimers Dis; 2022; 9(2):211-220. PubMed ID: 35542992
[TBL] [Abstract][Full Text] [Related]
9. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
[TBL] [Abstract][Full Text] [Related]
10. Amyloid-Related Imaging Abnormalities: An Update.
Roytman M; Mashriqi F; Al-Tawil K; Schulz PE; Zaharchuk G; Benzinger TLS; Franceschi AM
AJR Am J Roentgenol; 2023 Apr; 220(4):562-574. PubMed ID: 36321981
[TBL] [Abstract][Full Text] [Related]
11. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
Liu E; Wang D; Sperling R; Salloway S; Fox NC; Blennow K; Scheltens P; Schmidt ME; Streffer J; Novak G; Einstein S; Booth K; Ketter N; Brashear HR;
Neurology; 2018 Mar; 90(10):e877-e886. PubMed ID: 29429971
[TBL] [Abstract][Full Text] [Related]
12. Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
Filippi M; Cecchetti G; Spinelli EG; Vezzulli P; Falini A; Agosta F
JAMA Neurol; 2022 Mar; 79(3):291-304. PubMed ID: 35099507
[TBL] [Abstract][Full Text] [Related]
13. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
Honig LS; Sabbagh MN; van Dyck CH; Sperling RA; Hersch S; Matta A; Giorgi L; Gee M; Kanekiyo M; Li D; Purcell D; Dhadda S; Irizarry M; Kramer L
Alzheimers Res Ther; 2024 May; 16(1):105. PubMed ID: 38730496
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.
Sperling RA; Jack CR; Black SE; Frosch MP; Greenberg SM; Hyman BT; Scheltens P; Carrillo MC; Thies W; Bednar MM; Black RS; Brashear HR; Grundman M; Siemers ER; Feldman HH; Schindler RJ
Alzheimers Dement; 2011 Jul; 7(4):367-85. PubMed ID: 21784348
[TBL] [Abstract][Full Text] [Related]
15. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
Delnomdedieu M; Duvvuri S; Li DJ; Atassi N; Lu M; Brashear HR; Liu E; Ness S; Kupiec JW
Alzheimers Res Ther; 2016 Mar; 8(1):12. PubMed ID: 26925577
[TBL] [Abstract][Full Text] [Related]
16. Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report.
Sotoudeh H; Alizadeh M; Shahidi R; Shobeiri P; Love N; Singhal A
Radiol Case Rep; 2023 Jan; 18(1):275-279. PubMed ID: 36388611
[TBL] [Abstract][Full Text] [Related]
17. Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities.
Bechten A; Wattjes MP; Purcell DD; Aliaga ES; Daams M; Brashear HR; Arrighi HM; Barkhof F
J Neuroimaging; 2017 May; 27(3):318-325. PubMed ID: 28102639
[TBL] [Abstract][Full Text] [Related]
18. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis.
Jeong SY; Suh CH; Shim WH; Lim JS; Lee JH; Kim SJ
Neurology; 2022 Nov; 99(19):e2092-e2101. PubMed ID: 36038268
[TBL] [Abstract][Full Text] [Related]
20. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.
Hampel H; Elhage A; Cho M; Apostolova LG; Nicoll JAR; Atri A
Brain; 2023 Nov; 146(11):4414-4424. PubMed ID: 37280110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
